ABUS vs PODD · P/E 5.4, rev $6.2M vs P/E 34, rev $2.07B
Arbutus Biopharma Corp (ABUS) versus Insulet Corporation (PODD) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Insulet Corporation (PODD) is a medical devices company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported PODD revenue for 2024-12-31 was $2.07B. Net income was $418.3M. Revenue was up 22.1% from 2023-12-31 to 2024-12-31. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
Not investment advice. Open the ABUS and PODD stock pages for the full models.
Not investment advice.